PARP1 and diffuse large B-cell lymphoma: Capivasertib monotherapy had minimal effect on BCL-2 and BCL-XL protein levels or apoptotic biomarkers however, the combination increased PARP1 and caspase-3 cleavage in both GCB-DLBCL cell lines.